E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.

doi:10.1097/HEP.0000000000001461

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.

Hepatology (Baltimore, Md.) - 1 May 2026

Apodaka-Biguri Maider, Simão André L, González-Romero Francisco, Mestre Daniela, Rodrigues Pedro M, Aurrekoetxea Igor, Gómez-Santos Beatriz, Buqué Xabier, Nieva-Zuluaga Ane, de Gauna Mikel Ruiz, Fernandez-Puertas Idoia, Gomez-Jauregui Paul, Sainz-Ramirez Natalia, Alfaro-Jiménez Kendall, Ortiz-Palma Ane, Castillero Estibaliz, Iglesias-Ara Ainhoa, Mitxelena Jone, Eriz Ainhoa, Aransay Ana M, Lozano Juan-José, Marin Jose J G, Izquierdo-Sanchez Laura, Perugorria Maria J, Bujanda Luis, Banales Jesus M, Martín César, Mosteiro Lorena, Errazti Gaizka, Syn Wing-Kin, Castaño Luis, Zubiaga Ana M, Castro Rui E, Aspichueta Patricia

Abstract excerpt

BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a heterogeneous group of patients. Among them, those with a cholestatic profile show worse outcomes. Here, we investigated whether E2F2 is involved in MASLD-associated cholestasis and, if so, the role of miRNAs. APPROACH AND RESULTS: E2f2 -knockout ( E2f2-/- ) and wild-type (WT) mice were fed a choline-deficient high-fat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Acids and Salts

Share to Cholestasis

Share to Cholesterol

Share to Diet, High-Fat

Share to Fatty Liver

Share to Liver

Share to MicroRNAs

Share to Non-alcoholic Fatty Liver Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 40720724
DOI: 10.1097/HEP.0000000000001461
PMCID: PMC13089840

Genes

E2F2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.PMID 40720724Read ↗

Loss of hepatic FTCD promotes lipid accumulation and hepatocarcinogenesis by upregulating PPARγ and SREBP2Semantic proximity Read ↗

The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics studySemantic proximity Read ↗

Mechanistic basis for protection against fatty liver disease by <i>CIDEB</i> loss-of-function mutationsSemantic proximity Read ↗

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitisSemantic proximity Read ↗

Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axisSemantic proximity Read ↗

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progressionSemantic proximity Read ↗

Liver-Specific Deletion of Mouse CTCF Leads to Hepatic Steatosis via Augmented PPARγ Signaling.Semantic proximity Read ↗

Sex differences in bile acid homeostasis and excretion underlie the disparity in liver cancer incidence between males and femalesSemantic proximity Read ↗

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.Semantic proximity Read ↗

NPAS2 Promotes MASLD and Hepatocarcinogenesis through SIRT1-Mediated PPARγ SuppressionSemantic proximity Read ↗

Characterization of the metabolic pathways and hepatic macrophage subsets in mouse models of MASHSemantic proximity Read ↗

CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.